---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-015522"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T03:37:06.687824+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals announces positive preclinical data for Telomir-1 in progeria cell lines

## Summary
- Telomir-1 significantly increased cell viability in human HGPS cells under basal and metal-toxic conditions.
- Telomir-1 normalized reactive oxygen species (ROS) levels in Progeria cells, reducing oxidative stress.
- Telomir-1 reversed calcium overload, restoring mitochondrial function and energy balance.
- Company is finalizing IND-enabling studies and plans to engage FDA for orphan drug designation.
- Data builds on prior Telomir-1 results in Werner syndrome models (zebrafish, C. elegans) showing lifespan extension.

## SEC filing metadata
- accession: 0001641172-25-015522
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225015522/0001641172-25-015522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225015522/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-015522
- JSON: https://secwatch.observer/filing/0001641172-25-015522.json
- Plain text: https://secwatch.observer/filing/0001641172-25-015522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.